Cardiol Therapeutics is expanding its Phase III MAVERIC trial after reaching its enrollment target, with topline results now anticipated in mid-2027. The company expects existing Capital to fund completion and maintain its cash runway into Q1 2028, giving investors a stated financing horizon for the pivotal study.
Key Highlights
- MAVERIC’s primary efficacy measure is the time until a patient experiences a first new pericarditis recurrence.
- The study uses a randomized, double-blind, placebo-controlled, multi-center design.
- Cardiol Therapeutics has reached the enrollment goal for its Phase III MAVERIC trial and is expanding the study.
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a biotechnology company. It has reached the enrollment goal for its Phase III MAVERIC trial and is expanding the study, with topline results now anticipated in mid-2027.
MAVERIC Enrollment Moves Beyond Original Goal
The trial evaluates CardiolRx™ in patients with recurrent pericarditis. A blinded review found fewer recurrences than expected among randomized participants, an observation Cardiol views as encouraging. The MAVERIC Steering Committee recommended increasing enrollment to capture enough events for a stronger assessment of CardiolRx™’s potential to reduce recurrence risk. The company expects the expanded study and its completion to support the planned clinical readout in mid-2027. MAVERIC’s primary analysis will examine the time to a first new pericarditis recurrence, while the proportion of patients remaining free from a new episode at study end serves as a secondary endpoint.
Existing Capital Expected to Fund Trial Completion
Cardiol Therapeutics expects its existing capital to finance completion of MAVERIC. The company said the enrollment expansion is intended to provide the event count needed to preserve the trial’s planned statistical power. The study is evaluating whether CardiolRx™ can delay or prevent recurrence over time.
FAQs
Q: What does the Cardiol Therapeutics MAVERIC trial measure?
A: MAVERIC’s primary efficacy analysis measures the time to a first new episode of recurrent pericarditis. Its secondary endpoint assesses the proportion of patients free from a new episode at study completion.
Q: How is the MAVERIC Phase III trial designed?
A: The MAVERIC trial is randomized, double-blind, placebo-controlled and multi-center. It evaluates CardiolRx™ in patients with recurrent pericarditis.
Q: What is the identifier for Cardiol Therapeutics’ completed MAvERIC-Pilot study?
A: The article does not provide an identifier for the MAvERIC-Pilot study. It states only that MAVERIC is a Phase III trial evaluating CardiolRx™ in patients with recurrent pericarditis.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.